期刊文献+

冠心病冠脉介入治疗并发症的观察与分析

下载PDF
导出
摘要 目的分析冠心病冠脉介入治疗并发症,并提出有效的干预措施。方法将我院在2017年3月至2019年3月期间收治的90例冠心病患者作为本次的研究治疗,回顾患者的病历资料,所有患者均在本院接受冠脉治疗,依据不同护理措施进行分组,一组采取常规护理,一组采取综合护理,分别作为对照组和干预组,观察患者的并发症情况,分析其护理效果。结果干预组治疗有效率与对照组比较不存在统计学意义(P>0.05);干预组患者并发症发生率为4.44%(2例),2例均为急性闭塞;对照组并发症发生率为17.78%(8例),其中冠状动脉痉挛患者3例,无复流者2例,冠状动脉夹层者1例,室颤患者1例,内急性血栓形成3例,数据差异有统计学意义(P<0.05)。结论冠心病患者行冠脉介入治疗疗效显著,可有效解除冠脉梗阻情况,但并发症较多,可通过采取综合护理干预措施提高手术治疗效果,降低并发症。
作者 李丹成
出处 《心血管病防治知识(学术版)》 2019年第19期23-25,共3页 Prevention and Treatment of Cardiovascular Disease
  • 相关文献

参考文献7

二级参考文献46

  • 1Tang EW,Wong CK,Herbison P,et al. Global registry of acute coro-nary events (GRACE) hospital discharge risk score accurately pre-dicts long - term mortality post acute coronary syndrome [j]. AmHeart J,2007,153(1): 29-35.
  • 2Donahoe SM,Stewart GC,McCabe CH,et al. Diabetes and mortalityfollowing acute coronary syndromes [J]. JAMA, 2007, 298 (7):765-775.
  • 3Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for themanagement of acute coronary syndromes in patients presentingwithout persistent ST-segment elevation: the task force for the man-agement of acute coronary syndromes (ACS) in patients presentingwithout persistent ST-segment elevation of the European Society ofCardiology (ESC)[J]_Eur Heart J,2011,32(23) :2999-3054.
  • 4Goldberg U. Why does diabetes increase atherosclerosis? I don'tknow [J]. J Clin Invest,2004,114(5) :613-615.
  • 5Patti G,Proscia C, Di Sciascio G. Antiplatelet therapy in patientswith diabetes mellitus and acute coronary syndrome [j]. Circ J,2014,78(1):33-41.
  • 6Hong YJ, Jeong MH, Choi YH, et al. Plaque characteristics in cul-prit lesions and inflammatory status in diabetic acute coronary syn-drome patients [j]. JACC, Cardiovasc Imaging, 2009, 2 (3):339-349.
  • 7Rath PC,Chidambaram S,Rath P, et al. A study on the impact ofCYP2C19 genotype and platelet reactivity assay on patients undergo-ing PCI [J]. Indian Heart J,2015,67(2) : 114-121.
  • 8del Castillo-Camevali H, Barrios Alonso V,Zamorano G,et al. Anti-platelet therapy : resistance to traditional antiaggregation drugs androle of new antiplatelet agents [j]. Med Clin (Bare),2014,143(5):222-229.
  • 9Serebruany VL. Adenosine release: a potential explanation for thebenefits of ticagrelor in the PLATelet inhibition and clinical out-comes trial? [j]. Am Heart J,2011,161( 1) : 1-4.
  • 10Wallentin L, Becker RC, Budaj A, et al. Ticagrelor vs. clopidogrelin patients with acute coronary syndrome [j]. N Engl J Med,2009,361(11):1045-1057.

共引文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部